Shire scores a patent victory for Lialda, but PTO review looms

Shire ($SHPG) has scored a victory in its quest to protect its patent on ulcerative colitis med Lialda. Tuesday, it said the U.S. District Court for Southern Florida had upheld Lialda's IP shield, determining after a lengthy journey through the court system that a copy from Allergan's ($AGN) generics unit infringed on that patent. But while Shire may be breathing easier now, it's not completely out of the woods. Pharma patent challenger Kyle Bass, utilizing the U.S. Patent Trademark Office (PTO) inter partes review system, in October scored a review of Lialda's patent protection, meaning that the Patent Trial and Appeal Board could nix that IP within the year. Release | More

Suggested Articles

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

A U.S. appeals court called Maryland's groundbreaking price-hike law unconstitutional, sending legislators back to the drawing board.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.